Grafa News and Videos — Page 131

Bank7 Corp. (NASDAQ:BSVN) agreed to acquire 100% of Century Financial Services Corporation, the parent company of Century Bank, under a definitive merger agreement announced September 17, 2026.

Nuvation Bio (NASDAQ:NUVB) received U.S. Food and Drug Administration approval for a supplemental New Drug Application updating efficacy information for IBTROZI (taletrectinib) in TKI-naïve adults with advanced ROS1-positive non-small cell lung cancer.

Bristol Myers Squibb (NYSE:BMY) reported positive two-year results from the Phase 3 POETYK PsA-2 study and its open-label extension, showing continued efficacy and a consistent safety profile for Sotyktu (deucravacitinib) in adults with active psoriatic arthritis.

AECOM (NYSE:ACM) announced that its Board of Directors declared a quarterly cash dividend of $0.31 per share as part of its ongoing dividend program.

Indivior Pharmaceuticals (NASDAQ:INDV) declared a contingent special cash dividend of $8.13 per share, with payment dependent on the completion of its pending merger with Supernus Pharmaceuticals.

Centrus Energy (NYSE:LEU) signed a definitive multi-year contract to supply High-Assay Low-Enriched Uranium (HALEU) to Antares Nuclear, with deliveries scheduled to begin before the end of the decade.

Aquestive Therapeutics (NASDAQ:AQST) resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration for Anaphylm (dibutepinephrine) sublingual film, a treatment candidate for Type I allergic reactions including anaphylaxis.

NGL Energy Partners (NYSE:NGL) announced that its Board of Directors declared quarterly distributions for its Class B, Class C and Class D preferred units for the quarter ending September 30, 2026.

Surf Air Mobility (NYSE:SRFM) announced a definitive agreement with Sprintbach Aviation for OperatorOS, its SurfOS flight operations software platform for Part 135 operators powered by Palantir Technologies (NASDAQ:PLTR).

Aethlon Medical (NASDAQ:AEMD) and North Immunology entered a definitive all-stock merger agreement that will combine the companies around NOR-101, a half-life extended IL-13 x IL-18 bispecific antibody being developed for atopic dermatitis and other immune-mediated diseases.